VWM
KNSA icon

Vigilare Wealth Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Vigilare Wealth Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-22,720
Closed -$226K – 130
2022
Q1 		$226K Sell
22,720
-2,950
-11% -$31.3K 0.19% 122
2021
Q4 		$302K Buy
25,670
+2,170
+9% +$26.7K 0.18% 137
2021
Q3 		$268K Buy
23,500
+4,700
+25% +$61.2K 0.17% 155
2021
Q2 		$262K Buy
18,800
+7,955
+73% +$121K 0.16% 164
2021
Q1 		$201K Buy
+10,845
New +$222K 0.14% 183

Other funds holding KNSA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $2.4B AUM 42.85% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Vigilare Wealth Management's KNSA Position: Q2 2022 in Review

Vigilare Wealth Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q2 2022, closing a stake of 22,720 shares — an estimated $226K sold.

Vigilare Wealth Management first reported a position in KNSA in Q1 2021 and held it in 5 quarters. The position peaked at $302K in Q4 2021. 92 funds tracked by Wall St. Rank hold KNSA as of Q2 2022.

  • Vigilare Wealth Management reported no remaining Kiniksa Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Vigilare Wealth Management sold 22,720 Kiniksa Pharmaceuticals shares in Q2 2022, an estimated $226K.
  • Vigilare Wealth Management first reported a position in Kiniksa Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Vigilare Wealth Management's Kiniksa Pharmaceuticals position peaked at $302K in Q4 2021.
  • 92 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2022.

Based on Vigilare Wealth Management's 13F filing for Q2 2022, filed 11 Jul 2022.